The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice

Int J Antimicrob Agents. 2008 Aug;32(2):195-6. doi: 10.1016/j.ijantimicag.2008.03.016. Epub 2008 Jun 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Clarithromycin* / pharmacology
  • Clarithromycin* / therapeutic use
  • Disease Models, Animal
  • Escherichia coli / metabolism
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Infections* / mortality
  • Humans
  • Lipopolysaccharides / administration & dosage*
  • Mice
  • Mice, Inbred BALB C
  • Shock, Septic* / drug therapy
  • Shock, Septic* / mortality
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Clarithromycin